Goldman Sachs Reinstates Buy on Iovance Biotherapeutics, Announces $15 Price Target

Benzinga · 1d ago
Goldman Sachs analyst Andrea Newkirk reinstates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and announces $15 price target.